Scholars@Duke
Katherine Barnett Peters

Katherine Barnett Peters

Professor of Neurosurgery
Neurosurgery, Neuro-Oncology
katherine.peters@duke.edu
047 Baker House, Trent Drive, BOX_3624, Durham, NC 27710
Office hours Per Request  

Available to Mentor

  • Faculty
  • Fellow
  • Undergraduate

Advising & Mentoring

Fellow: Kristen Batich, Kaleigh Fetcko-Fayad, Avani Mangoli, Katherine Ryan
Faculty: Mallika Patel, Margaret Johnson, Justin Low
Resident: Dylan Ryan (Neurology), Eugene Vaios (Radiation Oncology)

Fellowship Since 2012

Danijela Levacic, MD

Adult Neurology

1. Levacic D and Peters, K.B. Characterization of Radiation Necrosis in Long-Term Survivors of Primary Glioblastoma.   Abstract NO-12. Annual Meeting of the American Academy of Neurology 2012, March 22nd.

2. Peters, K., Woodring, S., Affronti, M.L., Threatt, S., Lindhorst, S., Levacic, D., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, A., and Friedman, H.:  Neurocognitive dysfunction in newly diagnosed high-grade glioma patients: utilization of standardized computerized neurocognitive testing.  Abstract NC-018.  2013 SNO Annual Meeting, November 21-24, 2013, San Francisco, CA.  Neuro-Oncol. 15, Suppl. 3: iii73, 2013.

07/2012-06/2013

1 year

Physician, Neuro-Oncology

Baylor Scott & White Cancer Center – Round Rock

Round Rock, TX

Scott Lindhorst, MD

Medical Oncology

  1. Lindhorst, S.M., McSherry, F., Desjardins, A., Friedman, H.S., and Peters, K.B.:  Anaylsis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.  Abstract 2090.  2013 ASCO Annual Meeting, May 31-June 4, 2013, McCormick Place, Chicago, IL. J. Clin. Oncol. 31, Suppl. (15S, Part I): 136s, 2013.
  2. Peters, K., Woodring, S., Affronti, M.L., Threatt, S., Lindhorst, S., Levacic, D., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, A., and Friedman, H.:  Neurocognitive dysfunction in newly diagnosed high-grade glioma patients: utilization of standardized computerized neurocognitive testing.  Abstract NC-018.  2013 SNO Annual Meeting, November 21-24, 2013, San Francisco, CA.  Neuro-Oncol. 15, Suppl. 3: iii73, 2013.

07/2012-06/2013

1 year

Associate Professor of Neurosurgery, Medical University of South Carolina, Charleston, SC

Dina Randazzo, DO

Adult Neurology

  1. Peters, K., Threatt, S., Healy, P. Herndon, J.E. II, Lipp,E., Panta, S., Randazzo, D., Vlahovic, G., Friedman, H.S. and Desjardins, A.: Perceived cognitive dysfunction at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients.  Abstract PS060.  2017 MASCC Annual Meeting, June 22-24, 2017, Washington DC.
  2. Barboriak, D.P, Woodring, S., Panta, S., Lipp, E. , McSherry, F. , Herndon, J.E. II, Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B. Scan-rescan Repeatability of Hippocampal Volume Measurements in Patients with Low-grade Glioma: Comparison of Automated Software Packages Presented at American Society of Neuroradiology meeting, June 5, 2018, Vancouver, Canada.
  3. Peters, K.B., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Friedman, H.S., and Desjardins, A.:  Cognitive performance at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients.  2018 MASCC Annual Meeting, June 28-30, 2018, Vienna, Austria.
  4. Peters, K.B., Affronti, M.L., Woodring, S., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Desjardins, A., and Friedman, H.S. Taking sides: importance of tumor laterality in understanding cognitive testing in primary brain tumor patients.  2019 MASCC Annual Meeting, June 21-33, 2019, San Francisco, CA.
  5. Peters, K.B., Kirkpatrick J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Lipp, E., Boyd, K., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Crapo, J.:  First in human clinical trial of metalloporphyrin dual radioprotectant and radiosensitizer, BMX-001, in newly diagnosed high-grade glioma undergoing concurrent chemoradidation.  Poster 2239. 2019 ASTRO Annual Meeting, September 15-18, 2019, Chicago, IL.
  6. Peters, K., Congdon, K., Archer, G., Woodring, S., Jaggers, D., Lipp, E., Healy, P., Herndon, J., Soher, B., Vlahovic, G., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Friedman, A., Ashley, D., Yan, H., and Sampson, J.:  Safety of tumor-specific peptide vaccine targeting isocitrate dehydrogenase 1 mutation in recurrent resectable low grade glioma patients.  Abstract ATIM-31.  Neuro-Oncology 21(Suppl 6):vi8, 2019.
  7. Peters, K., Lipp, E., Broadwater, G., Herndon J. II, Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Affronti, M.:  Clinical characteristics of low grade glioma patients with non-canonical IDH1 and IDH2 mutations.  Abstract NCOG-38. 2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii137, 2020.
  8. Randazzo, D.M., Affronti, M.L., Lipp, E., McSherry, F., Herndon, J.E. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, H.F., and Peters, K.B.:  Complementary and alternative medicine in the primary brain tumor population and its association with health-related quality of life.  Abstract MASCC-0215.  2014 MASCC Annual Meeting, June 26 – 28, 2014, Miami, FL. Supp. Care Cancer 22, Suppl. 1: S191, 2014.
  9. Peters, K., Reardon, D., Randazzo, D., Dutton, S., Edwards, A., Lipp, E., Herndon, J. II, McSherry, F., Desjardins, A., Ranjan, T., Vlahovic, G., and Friedman, H.:  Vorinostat and bevacizumab for recurrent high-grade glioma: interim analysis of a phase II clinical trial.  Abstract AT-46.  2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL.  Neuro-Oncol. 16, Suppl. 5: v128 2014.
  10. Peters, K., Randazzo, D., Affronti, M., Lipp, E., McSherry, F., Herndon, J. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Ranjan, T., Vlahovic, G., Jones, L., and Friedman, H.:  Prognostic importance of health-related quality of life and fatigue in newly diagnosed glioblastoma.  Abstract QL-20.  2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL.  Neuro-Oncol. 16, Suppl. 5: v182, 2014.
  11. Randazzo, D., Affronti, M., Lipp, E., McSherry, F., Herndon, J. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, H., and Peters, K.:  Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.  Abstract QL-21.  2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL.  Neuro-Oncol. 16, Suppl. 5: v182, 2014.
  12. Peters, K.B., Affronti, M.L., Woodring, S., Lipp, E., Healy, P., McSherry, F., Herndon, J.E., Flahiff, C., Miller, E., Freeman, M., Minchew, J., Zalutsky, B., Taylor, B., Boulton, S., Randazzo, D., Desjardins, A., Vlahovic, G., Bigner, D.D., and Friedman, H.S.:  Placebo-controlled, double-blind, randomized pilot study to evaluate the effects of low-dose naltrexone on quality of life and fatigue in newly diagnosed high-grade glioma.  Abstract P4.210. 2015 AAN Annual Meeting.  April 18-25, 2015, Washington, DC.

 

  1. Randazzo, D., Affronti, M.L., Lipp, E., McSherry, F., Herndon, J.E. II, Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S.B., Desjardins, A., Ranjan, T., Vlahovic, G., Friedman, H.S., and Peters, K.B.:  Complementary and alternative medicine in the primary brain tumor population and its association with health reported Quality of Life.  Abstract S18.007.  2015 AAN Annual Meeting.  April 18-25, 2015, Washington, DC.
  2. Desjardins, A., Sampson, J.H., Peters, K.B., Vlahovic, G., Randazzo, D., Threatt, S., Herndon, J.E., Boulton, S., Lally-Goss, D., McSherry, F., Lipp, E.S., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Gromeier, M.M.: Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. Abstract 2068. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

10. Desjardins, A., Peters, K.B., Vlahovic, G., Randazzo, D., Boulton, S., Massey, W.C., Lipp, E.S., Herndon, J.E., Healy, P., Miller, E., Karmali, R.A., and Friedman, H.S.: Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. Abstract 2067. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

11. Vlahovic, G., Archer, G.E., Lally-Goss, D., Reap, E., Desjardins, A., Peters, K.B., Randazzo, D., Healy, P., Herndon, J.E., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.:  Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). Abstract e13030. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

12. Kim, J.Y., Woodring, S., Affronti, M.L., Randazzo, D., McSherry, F., Herndon, J.E., Lipp, E.S., Desjardins, A., Vlahovic, G., Friedman, H.S., and Peters, K.B.:  Secondary cancers in long-term survivors of primary glioblastoma.  Abstract e20616. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

13. Randazzo, D.M., McSherry, F., Herndon, J.E., Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H.S., Keir, S.T. and Peters, K.B.:  Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. Abstract 9553.  2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

14. Ghiaseddin, A., Reardon, D.R., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E., McSherry, F., Desjardins, A., Randazzo, D.A., Vlahovic, G., Friedman, H.S., and Peters, K.B.: Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.  Abstract 2034. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

15. Friedman, H.S., Peters, K.B., Vlahovic, G., Randazzo, D., Boulton, S., Woodring, S., Lipp, E.S., Herndon, J.E., Healy, P., Miller, E., Karmali, R.A. and Desjardins, A.:  Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).  Abstract e13004.  2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

16. Brownstein, J., Randazzo, D., Kim, G., Peters, K., and Kirkpatrick, J.:  A simple kinetic model provides an early prediction of thrombocytopenia in malignant glioma patients treated with radiation and temozolomide.  Abstract.  2015 57th ASTRO Annual Meeting, October 18-22, 2015, San Antonio, TX. 

17. Affronti, M.L., Friedman, H.S., Desjardins, A., Vlahovic, G., Randazzo, D.M., Herndon, J.E., McSherry, F., Lipp, E.S., Mannerino, A., Massey, W., Miller, E., Iden, D., Peters, K.B.: Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG). Abstract ATCT-01. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v1, 2015.

18. Weant, M., Dunn-Pirio, A., Peters, K., Vlahovic, G., Randazzo, D., Herndon, J.E. II, Healy, P., Threatt, S., Sampson, J., Friedman, A., Friedman, H., Desjardins, A.:  Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. Abstract ATCT-13.  2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v4, 2015.

19. Vlahovic, G., Archer, G., Reap, E., Ghiaseddin, A., Desjardins, A., Peters, K., Randazzo, D., Healy, P., Herndon, J.E. II, Friedman, A., Friedman, H., Bigner, D., and Sampson, J.:  Combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM). Abstract IMCT-19. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v111, 2015.

20. Peters, K., Affronti, M., Woodring, S., Lipp, E., Healy, P., McSherry, F., Herndon, J.E. II, Flahiff, C., Miller, E., Freeman, M., Minchew, J., Zalutsky, B., Taylor, B., Boulton, S., Randazzo, D., Desjardins, A., Vlahovic, G., Bigner, D., and Friedman, H.:  Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study. Abstract QOL-20.  2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v192, 2015.

21. Randazzo, D.M., McSherry, F., Herndon, J.E. II, Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H.S., and Peters, K.B.:  Diet and health-related quality of life (HRQoL) in the primary brain tumor population. Abstract QOL-21. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v192, 2015.

22. Desjardins, A. Sampson, J.H., Peters, K.B., Vlahovic, G., Randazzo, D., Threatt, S., Herndon, J.E., Boulton, S., Lally-Goss, D., McSherry, F., Lipp, E.S., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Gromeier, M.:  Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).   Abstract 2061.  2016 ASCO Annual Meeting. June 3 – 7, 2016, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 34(15s), 107s, 2016.

23. Peters, K.B., Woodring, S., Healy, P., Herndon, J.E., Lipp, E.S., Minchew, J., Zalutsky, B., Affronti, M., Randazzo, D., Desjardins, A., Vlahovic, G., and Friedman, H.S.:  Baseline cognitive function to predict survival in patients with glioblastoma.  Abstract 10125.  2016 ASCO Annual Meeting. June 3 – 7, 2016, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 34(15s), 541s, 2016.

24. Vlahovic, G., Archer, G.E., Reap, E. Desjardins, A., Peters, K.B., Randazzo, D., Healy, P., Herndon, J.E., Friedman, A.H., Friedman, H.S., Bigner, D.D. and Sampson, J.H.:  Phase 1 trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in paitents with newly-diagnosed glioblastoma multiforme (GBM).  Abstract e13518.  2016 ASCO Annual Meeting. June 3 – 7, 2016.  Pro. J Clin Oncol. 34(15s), 2016.

25. Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., and Bigner, D.:  Phase I dose escalation study of D2C7-IT administered intratumorally via convection-enhanced deliver (CED) for recurrent malignant glioma (MG).  Abstract ATIM-18.  2016 SNO Annual Meeting.  November 17-20, 2016, Scottsdale, AZ.   Neuro-Oncology 18:vi21, 2016.

26. Peters, K., Affronti, M.L., Woodring, S., Minchew, J., Lipp, E., McSherry, F., Herndon, J., Randazzo, D., Desjardins, A., Vlahovic, G., Friedman, H., and Barboriak, D.:  Neurocognition in low-grade gliomas: associations with measurable and perceived impairments.  Abstract NCOG-12.  2016 SNO Annual Meeting.  November 17-20, 2016, Scottsdale, AZ.   Neuro-Oncology 18:vi122, 2016.

27. Randazzo, D., McSherry, F., Herndon, J., Affronti, M.L., Lipp, E., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H., Keir, S., and Peters, K.:  A cross-sectional study of distress throughout disease trajectory in primary brain tumor patients.  Abstract QLIF-20.  2016 SNO Annual Meeting.  November 17-20, 2016, Scottsdale, AZ.   Neuro-Oncology 18:vi160, 2016.

28. Desjardins, A., Sampson, J.H., Vlahovic, G., Peters, K.B., Randazzo, D., Threatt, S., Herndon, J.E., Bullock, C.A., Miller, E.S., Boulton, S., Lally-Goss, D., McSherry, F., Lipp, E.S., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Gromeier, M.:  Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).  Abstract e13533.  2017 ASCO Annual Meeting, June 2-5, 2017, Chicago, IL.  J Clin Oncol 35, 2017.

29. Randazzo, D., Desjardins, A., Chandramohan, V., Sampson, J.H., Peters, K.B., Vlahovic, G., Threatt, S., Herndon, J.E., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E.S., Friedman, A.H., and Bigner, D.D.:  Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma. Abstract e13532.  2017 ASCO Annual Meeting, June 2-5, 2017, Chicago, IL.  J Clin Oncol 35, 2017.

30. Peters, K.B., Threatt, S., Healy, P., Herndon, J.E., Lipp, E.S., Panta, S., Randazzo, D., Vlahovic, G., Friedman, H.S., and Desjardins, A.:  Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.  Abstract e21636.  2017 ASCO Annual Meeting, June 2-5, 2017, Chicago, IL.  J Clin Oncol 35, 2017.

31. Weant, E., Woodring, S., Randazzo, D.M., Friedman, H.F., Desjardins, A., Vlahovic, G., Healy, P.,  Herndon, J.E. II , McSherry, F., Lipp, E.,Miller, E., Cone, C., Kim, J.Y., Southerland, C., Brown, C., Carter, M., Johnson, M.P., Peters, K.B, and Affronti, M.L.,:  Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.  Abstract MASCC-EP178.  2017 MASCC Annual Meeting, June 22-24, 2017, Washington DC. Supp. Care Cancer 25, Suppl. 2: S266, 2017.

32. Desjardins, A., Randazzo, D., Peters, K.B., Johnson, M.O., Massey, W., Herndon, J.E. II, McSherry, F., Lipp, E.S., Nadler, P., Horak, I.D., Friedman, H.S.: Phase 2 Study of SYM004 for Adult Patients with Recurrent Glioblastoma (GBM). Abstract ACTR-64. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi303, 2017.

33. Dunn-Pirio, A., Woodring, S., Panta, S., Lipp, E.S., Healy, P., Herndon, J.E. II, Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: Perampanel for treatment of refractory Seizures in patients with gliomas. Abstract PALL-02.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi168, 2017.

34. Peters, K.B., Affronti, M.L., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Friedman, H.S., Desjardins, A.: Increased fatigue associated with tumor progression in newly diagnosed glioblastoma (gbm) patients. Abstract PALL-10.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi170, 2017.

35. Randazzo, D., McSherry, F., Herndon, J.E. II, Affronti, M.L., Healy, P., Lipp, E.S., Desjardins, A., Friedman, H.S., Peters, K.B.:  A single institution’s experience exploring the association of integrative medicine and survivorship in glioblastoma. Abstract QLIF-05.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi202, 2017.

36. Peters, K.B., Affronti, M.L., Threatt, S., Healy, P., Herndon, J.E. II, Lipp, E.S., Panta, S., Randazzo, D., Friedman, H.S., Desjardins, A.: Maintenance of health related quality of life (qol) beyond progression in newly diagnosed glioblastoma patients treated with bevacizumab. Abstract QLIF-22.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi206, 2017.

37. Affronti, M.L., Randazzo, D., Peters, K.B., Herndon, S.C., Healy, P., Herndon, J.E., Woodring, S., Hawkins, K., Lipp, E.S., Kohrman, O., Desjardins, A., Vlahovic, G., Friedman, H.S., Kim, J.Y., Miller, E.S., Schneider, S.: Pilot study to describe the trajectory of symptoms and adaptive strategies of adults living with low grade gliomas (lgg). Abstract QLIF-34.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi208, 2017.

38. Johnson, M.O., Kirkpatrick, J.P., Weant, M.P., Dunn-Pirio, A., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.:  A retrospective, single institution study of central neurocytoma (2004-2016): survival, treatment, and supportive care. Abstract RARE-25.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi215, 2017.

39. Weant, M.P., Kirkpatrick, J., Johnson, M., Dunn-Pirio, A., Healy, P., Herndon, J.E. II, Lipp, E.S., Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.:  Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma. Abstract RARE-36.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi217, 2017.

40. Vaslow, Z., Peters, K., Kirkpatrick, J., McSherry, F., Herndon, J. II, Lipp, E., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., and Friedman, H.S.: Long-term outcomes of adult patients with ependymoma.  Abstract 150.  2018 70th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.

41. Inamullah, O., Kirkpatrick, J., Healy, P., Lipp, E., Johnson, M., Ashley, D., Randazzo, D., Friedman, H. and Peters, K.:  Adult pilocytic astrocytoma: clinical management and prognostic factors.  Abstract 158.  2018 70th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.

42. Peters, K.B., Kirkpatrick, J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Panta, S., Lipp, E., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D. and Crapo, J.:  Phase I dose escalation trial of the safety of BMX-001 concurrent with radiation therapy and temozolomide in newly diagnosed patients with high-grade glioma.  Abstract ACTR-28.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi17, 2018.

43. Ashley, D., Desjardins, A., Gromeier, M., Muscat, A., Herndon, J., Friedman, A., Friedman, H., McSherry, F., Randazzo, D., Peters, K., Threatt, S., Bullock, C., Miller, E., Boulton, S., Lipp, E., Bigner, D., and Sampson, J.: Intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in malignant glioma patients: assessment of mutational response correlates.  Abstract ATIM-27.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi7, 2018.

44. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Thomas, L., Threatt, S., Bullock, C., Herndon, J., Boulton, S., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.:  Dose escalation trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).  Abstract ATIM-36.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi9, 2018.

45. Johnson, M., Kirkpatrick, J., Weant, M., Vaslow, Z., Lipp, E., Herndon, J., McSherry, F., Desjardins, A., Randazzo, D., Friedman, H., Ashley, D., and Peters, K.:  Treatment patterns, outcomes and prognostic indicators in elderly patients with glioblastoma: a retrospective single institution analysis.  Abstract HOUT-19.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi117, 2018.

46. Randazzo, D., Kirkpatrick, J., McSherry, F., Herndon, J., Affronti, M., Johnson, M., Vaslow, Z., Lipp, E., Desjardins, A., Friedman, H., and Peters, K.:  Psychosocial distress in patients with recurrent meningiomas.  Abstract QOLP-13.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi217, 2018.

47. Affronti, M., Randazzo, D., Woodring, S., McSherry, F., Healy, P., Herndon, J., Weant, M., Miller, E., Lipp, E., Friedman, H., and Peters, K.:  Review and meta-analysis of nausea and vomiting trials for malignant glioma.  Abstract QOLP-17.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi218, 2018.

48. Vaslow, Z., Kirkpatrick, J., Affronti, M., Healy, P., Herndon, J., Lipp, E., Thomas, L., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Peters, K.:  Clinical and histopathological characteristics of young adults with glioblastoma at diagnosis.  Abstract RARE-16.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi239, 2018.

49. Kang, J., Swisher, C., Kirkpatrick, J., Herndon, J. II, Lipp, E., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., and Peters, K.:  Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study.  2019 AAN Annual Meeting, May 4-10, 2019, Philadelphia, PA. 

50. Desjardins, A., Gromeier, M., Herndon, J.E. II, Randazzo, D., Threatt, S., Lipp, E.S., Miller, E.S., Jackman, J., Bolognesi, D.P., Friedman, A.H., Friedman, H.S., McSherry, F., Peters, K.B., Johnson, M.O., Sampson, J.H., Ashley, D.M., and Bigner, D.D.:  Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): experience with retreatment of survivors from the phase I trial.  Abstract 2060.  2019 ASCO Annual Meeting, May 31 – June 4, 2019, Chicago, IL.  J Clin Oncol 37(15s):101s, 2019.

51. Lee, J.W., Johnson, M.O., Kirkpatrick, J.P., McSherry, F., Herndon, J., Lipp, E., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D., Peters, K.B.:  Outcomes following adjuvant radiation therapy in elderly patients with glioblastoma: a retrospective single institution analysis.  2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, McCormick Place West, Chicago, IL, September 15 – 18, 2019.

52. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Threatt, S., Bullock, C., Jackman, J., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.:  Dose finding and dose expansion trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).  Abstract ATIM-24.  Neuro-Oncology 21(Suppl 6):vi6, 2019.

53. Gromeier, M., Brown, M., Beuabier, N., Yan, H., He, Y., Zhang, G., Desjardins, A., Herndon, J., Bolognesi, D., Friedman, A., Friedman, H., McSherry, F., Lin, X., Wei, Z., Nair, S., Peters, K., Randazzo, D., Sampson, J., McLendon, R., Bigner, D., and Ashley, D.:  Tumor mutational burden predicts response to oncolytic polio/rhinovirus recombinant (PVSRIPO) in malignant glioma patients: assessment of transcriptional and immunological correlates.  Abstract ATIM-27. Neuro-Oncology 21(Suppl 6):vi7, 2019.

54. Barbour, A., Healy, P., Lipp, E., Herndon, J., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., Kirkpatrick, J., and Peters, K.:  Characteristics of short-term survival in patients with glioblastoma: a retrospective analysis.  Abstract HOUT-21.  Neuro-Oncology 21(Suppl 6):vi116, 2019.

55. Johnson, M., Ramirez, L., Herndon, J., Massey, W., Lipp, E., Affronti, M., Kim, J.-Y., Friedman, H., Desjardins, A., Randazzo, D., Ashley, D., Casarette, D., and Peters, K.:  A time-based model of early palliative care intervention in patients with newly diagnosed glioblastoma, a single institution feasibility study.  Abstract QOLP-18.  Neuro-Oncology 21(Suppl 6):vi201, 2019.

56. Randazzo, D., Jackman, J., Herndon, J., Affronti, M., Lipp, E., Cort, N., Desjardins, A., Johnson, A., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.:  Mindfulness meditation practice in malignant glioma patients throughout concomitant radiation and temozolomide: a feasibility study.  Abstract QOLP-29.  Neuro-Oncology 21(Suppl 6):vi204, 2019.

57. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K.B., Johnson, M.O., Threatt, S., Bullock, C.A., Herndon, J.E. II, Healy, P., Lipp, E.S., Sampson, J.H., Friedman, A.H., Friedman, H.S., Ashley, D.M., and Bigner, D.D.: Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract 2566.  2020 ASCO Virtual Annual Meeting, May 29 – 31, 2020.  J Clin Oncol 38(suppl), 2020.

58. Thompson, E., Landi, D., Lipp, E., Balajonda, B., Herndon, J. II, Buckley, E., Flahiff, C., Jaggers, D., Schroeder, K., Randazzo, D., Desjardins, A., Johnson, M., Peters, K., Khasraw, M., Malinzak, M., Mitchell, D., Ashley, D., and Sampson, J.:  Peptide vaccine directed to CMV PP65 for treatment of recurrent malignant glioma and medulloblastoma in children and young adults:  preliminary results of a phase I trial.  Abstract CTIM-21.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii37, 2020.

59. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Landi, D., Khasraw, M., Threatt, S., Bullock, C., Herndon, J. II, Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.:  A phase I trial of D2C7-IT in combination with atezolizumab in recurrent WHO grade IV malignant glioma (MG).  Abstract CTIM-23.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii38, 2020.

60. Johnson, M., Herndon, J. II, Lipp, E., Affronti, M., Desjardins, A., Bhattacharya, M., Friedman, H., Ashley, D., Peters, K., and Randazzo, D.:  Patterns of distress in older patients with glioblastoma:  a follow-up to a single institution cross-sectional study of distress in primary brain tumor patients.  Abstract NCOG-23.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii134, 2020.

61. Patel, M., Peters, K., Lipp, E., Low, J., Herndon, J. II, Broadwater, G., Johnson, M., Randazzo, D., Kim, J-Y., and Affronti, M.:  Olanzapine for refractory chemotherapy-induced nausea and vomiting in malignant glioma patients.  Abstract QOLP-05.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii175, 2020.

62. Randazzo, D., Buckley, E., Herndon, J. II, Cort, N., Affronti, M., Lipp, E., Desjardins, A., Johnson, M., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.:  A feasibility study utilizing mindfulness meditation during concomitant chemoradiation in malignant glioma patients: health-related quality of life (HRQOL) results.  Abstract QOLP-20.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii179, 2020.

 

63. Peters, K., Randazzo, D., Johnson, M., Kim, J-Y., Patel, M., and Affronti, M.:  Engaging patients and caregivers to improve the importance and quality of supportive care research in neuro-oncology.  Abstract QOLP-24.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii180, 2020.

  1. Randazzo, D. and Peters, K.B.:  Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.  CNS Oncol. 5:241-249, 2016.
  2. Randazzo, D.M., McSherry, F., Herndon, J.E. II, Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Freeman, M., Healy, P., Minchew, J., Boulton, S., Desjardins, A., Vlahovic, G., Friedman, H.S., Keir, S., and Peters, K.B.:  A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population.  J. Neurooncol. 134:363-369, 2017.
  3. Ghiaseddin, A., Reardon, D., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E. II, McSherry, F., Desjardins, A., Randazzo, D., Friedman, H.S., and Peters, K.B.:  Phase II study of bevacizumab and vorinostat for patients with recurrent World Health Organization Grade 4 malignant glioma.  Oncologist, 23:157-e21, 2018.
  4. Desjardins, A., Gromeier, M., Herndon, J.E. II, Beaubier, N., Bolognesi, D.P., Friedman, A.H., Friedman, H.S., McSherry, F., Muscat, A.M., Nair, S., Peters, K.B., Randazzo, D., Sampson, J.H., Vlahovic, G., Harrison, W.T., McLendon, R.E., Ashley, D., and Bigner, D.D.:  Recurrent glioblastoma treated with recombinant poliovirus.  N. Engl. J. Med. 379(2):150-161, 2018.
  5. Dunn-Pirio, A., Woodring, S., Lipp, E., Herndon, J.E. II, Healy, P., Weant, M., Randazzo, D., Desjardins, A., Friedman, H.S., and Peters, K.B.:  Adjunctive perampanel for refractory glioma-associated epilepsy.  Epilepsy Behav. Case Rep. 10:114-117, 2018.
  6. Affronti, M.L., Randazzo, D., Lipp, E.S., Peters, K.B., Herndon, S.C., Woodring, S., Healy, P., Cone, C.K., Herndon, J.E. II, and Schneider, S.M.:  Pilot study to describe the trajectory of symptoms and adaptive strategies of adults living with low-grade glioma.  Semin. Oncol. Nurs. 34(5):472-485, 2018.
  7. Desjardins, A., Herndon, J.E. II, McSherry, F., Ravelo, A., Lipp, E.S., Healy, P., Peters, K.B., Sampson, J.H., Randazzo, D., Sommer, N., Friedman, A.H., and Friedman, H.S.:  Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.  Health Sci. Rep. 2:e114, 2019.
  8. Randazzo, D.M., McSherry, F., Herndon, J.E., Affronti, M.L., Lipp, E.S., Flahiff, C., Miller, E., Woodring, S., Boulton, S., Desjardins, A., Ashley, D.M., Friedman, H.S., and Peters, K.B.:  Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.  Complementary Therapies Clin. Prac.  36:43-48, 2019.
  9. Patel, M.P., Woodring, S., Randazzo, D.M., Friedman, H.S., Desjardins, A., Healy, P., Herndon, J.E. II, McSherry, F., Lipp, E.S., Miller, E., Peters, K.B., and Affronti, M.L.:  Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.  Supp. Care Cancer. Published online ahead of print August 22, 2019.

10. Johnson, M.O., Kirkpatrick, J.P., Patel, M.P., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D.M., and Peters, K.B.:  The role of chemotherapy in the treatment of central neurocytoma.  CNS Oncol. Published online ahead of print November 5, 2019.

11. Patel MP, Kirkpatrick JP, Johnson MO, Healy P, Herndon JE 2nd, Lipp ES, Miller ES, Desjardins A, Randazzo D, Friedman HS, Ashley DM, Peters KB. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. J Neurooncol. 2020 Apr;147(2):477-483. doi: 10.1007/s11060-020-03446-3. Epub 2020 Mar 5. PMID: 32140975.

12. Gromeier M, Brown MC, Zhang G, Lin X, Wei Z, Beaubier N, Yan H, Desjardins A, Herndon JE II, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Lipp ES, Nair SK, Khasraw M, Peters KB, Randazzo D, Sampson JH, McLendon RE, Bigner DD, and Ashley DM: Very low mutation burden is a feature of inflamed recurrent glioblastomas responsibe to cancer immunotherapy.  Nat. Commun.  2021 Jan 13;12(1):352. doi: 10.1038/s41467-020-20469-6. PMID: 33441554.

13. Randazzo DM, McSherry F, Herndon JE II, Affronti ML, Lipp ES, Miller ES, Woodring S, Healy P, Jackman J, Crouch B, Desjardins A, Ashley DM, Friedman HS, Peters KB: Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.  Neuro-Onc. Prac. Published online ahead of print Feb 17, 2021.

14. Lee JW, Kirkpatrick JP, McSherry F, Herndon JE II, Lipp ES, Desjardins A, Randazzo DM, Friedman HS, Ashley DM, Peters KB, Johnson MO: Adjuvant radiation in older patients with glioblastoma: a retrospective single institution analysis. Front. Oncol. 2021 Feb 25:11:631618. doi: 10.3389/fonc.2021.631618. eCollection 2021.  PMID: 33732649.

 

07/2013-06/2014

1 year

 

 

Assistant Professor of Neurology and Neurosurgery, Duke University, Durham, NC

Passed on 2/20/2021

Kristin Schroeder, MD, MPH

Pediatric Hematology/Oncology

1. Thompson, E., Landi, D., Lipp, E., Balajonda, B., Herndon, J. II, Buckley, E., Flahiff, C., Jaggers, D., Schroeder, K., Randazzo, D., Desjardins, A., Johnson, M., Peters, K., Khasraw, M., Malinzak, M., Mitchell, D., Ashley, D., and Sampson, J.:  Peptide vaccine directed to CMV PP65 for treatment of recurrent malignant glioma and medulloblastoma in children and young adults:  preliminary results of a phase I trial.  Abstract CTIM-21.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii37, 2020.

 

07/2013-06/2014

1 year

Assistant Professor of Pediatrics

Duke University Medical Center

Durham, NC

Ashley Ghiaseddin, MD

Adult Neurology

1. Ghiaseddin, A., Dunn-Pirio, A., Peters, K., Vlahovic, G., Herndon, J. II, Threatt, S., Sampson, J., Friedman, A., Friedman, H., and Friedman, A.:  Phase II trial of bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression. Abstract AT-22.  2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL.  Neuro-Oncol. 16, Suppl. 5: v13, 2014.

2. Ghiaseddin, A., Reardon, D.R., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E., McSherry, F., Desjardins, A., Randazzo, D.A., Vlahovic, G., Friedman, H.S., and Peters, K.B.: Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.  Abstract 2034. 2015 ASCO Annual Meeting. May 29 – June 2, 2015, McCormick Place, Chicago, IL. Pro. J Clin Oncol. 33(15s), 2015.

3. Vlahovic, G., Archer, G., Reap, E., Ghiaseddin, A., Desjardins, A., Peters, K., Randazzo, D., Healy, P., Herndon, J.E. II, Friedman, A., Friedman, H., Bigner, D., and Sampson, J.:  Combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM). Abstract IMCT-19. 2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v111, 2015.

4. Ghiaseddin, A., West, M., Hornsby, W., Freeman, M., Lipp, E., McSherry, F., Herndon, J.E. II, Desjardins, A., Friedman, H., Jones, L., Peters, K.:  Prospective evaluation of cardiopulmonary fitness in newly diagnosed glioblastoma patients receiving an anti-angiogenic regimen. Abstract QOL-19.  2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v192, 2015.

2. Ghiaseddin, A. and Peters, K.B.:  Use of bevacizumab in recurrent glioblastoma.  CNS Oncol. 4(3): 157-169, 2015.

3. Ghiaseddin, A., Reardon, D., Massey, W., Mannerino, A., Lipp, E.S., Herndon, J.E. II, McSherry, F., Desjardins, A., Randazzo, D., Friedman, H.S., and Peters, K.B.:  Phase II study of bevacizumab and vorinostat for patients with recurrent World Health Organization Grade 4 malignant glioma.  Oncologist, 23:157-e21, 2018.

 

07/2014-06/2015

1 year

Clinical Associate Professor

University of Florida College of Medicine

Gainesville, FL

Tammy Hennika, MD

Pediatric Neurology

07/2014-06/2015

1 year

Clinical Assistant Professor of Pediatrics (Courtesy)

Weill Cornell Medicine

New York, NY

Simon Khagi, MD

Medical Oncology

1. Khagi, S., and Peters, K.B.: Antiangiogenic virotherapy: VB-111 targeting glioma.  Ex. Opin. Orphan Drugs. 4:1099-1103, 2016.

 

07/2015-06/2016

1 year

Medical Director of NCCC Sites, Dartmouth Cancer Center, Dartmouth University, NH

Anastasie Dunn-Pirio, MD

Adult Neurology

1. Ghiaseddin, A., Dunn-Pirio, A., Peters, K., Vlahovic, G., Herndon, J. II, Threatt, S., Sampson, J., Friedman, A., Friedman, H., and Friedman, A.:  Phase II trial of bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression. Abstract AT-22.  2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL.  Neuro-Oncol. 16, Suppl. 5: v13, 2014.

2. Weant, M., Dunn-Pirio, A., Peters, K., Vlahovic, G., Randazzo, D., Herndon, J.E. II, Healy, P., Threatt, S., Sampson, J., Friedman, A., Friedman, H., Desjardins, A.:  Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. Abstract ATCT-13.  2015 SNO Annual Meeting, November 19-22, 2015, San Antonio, TX.  Neuro-Oncology 17(Suppl 5):v4, 2015.

3. Dunn-Pirio, A., Woodring, S., Panta, S., Lipp, E.S., Healy, P., Herndon, J.E. II, Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.: Perampanel for treatment of refractory Seizures in patients with gliomas. Abstract PALL-02.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi168, 2017.

4. Johnson, M.O., Kirkpatrick, J.P., Weant, M.P., Dunn-Pirio, A., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.:  A retrospective, single institution study of central neurocytoma (2004-2016): survival, treatment, and supportive care. Abstract RARE-25.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi215, 2017.

5. Weant, M.P., Kirkpatrick, J., Johnson, M., Dunn-Pirio, A., Healy, P., Herndon, J.E. II, Lipp, E.S., Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.:  Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma. Abstract RARE-36.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi217, 2017.

1. Dunn-Pirio, A. and Peters, K.B.:  Weber’s syndrome due to low-grade astrocytoma.  Open J Clin Med Case Rep 1(1): 1005, 2015.

2. Dunn-Pirio, A., Billakota, S., and Peters, K.B.:  Postictal magnetic resonance imaging changes masquerading as brain tumor progression: a case report.  Case Rep. Oncol. 9:358-362, 2016.

3. Dunn-Pirio, A.M., Howell, E., McLendon, R.E., and Peters, K.B.:  Single-agent carboplatin for a rare case of pilomyxoid astrocytoma of the spinal cord in an adult with neurofibromatosis type 1.  Case Rep. Oncol. 9:568-573, 2016.

4. Dunn-Pirio, A., Woodring, S., Lipp, E., Herndon, J.E. II, Healy, P., Weant, M., Randazzo, D., Desjardins, A., Friedman, H.S., and Peters, K.B.:  Adjunctive perampanel for refractory glioma-associated epilepsy.  Epilepsy Behav. Case Rep. 10:114-117, 2018.

 

08/2015-08/2017

2 years

Assistant Professor, Department of Neurology

UC San Diego Health

San Diego, CA

Margaret Johnson, MD

Adult Neurology

  1. Peters, K.B., Kirkpatrick J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Lipp, E., Boyd, K., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Crapo, J.:  First in human clinical trial of metalloporphyrin dual radioprotectant and radiosensitizer, BMX-001, in newly diagnosed high-grade glioma undergoing concurrent chemoradidation.  Poster 2239. 2019 ASTRO Annual Meeting, September 15-18, 2019, Chicago, IL.
  2. Peters, K., Congdon, K., Archer, G., Woodring, S., Jaggers, D., Lipp, E., Healy, P., Herndon, J., Soher, B., Vlahovic, G., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Friedman, A., Ashley, D., Yan, H., and Sampson, J.:  Safety of tumor-specific peptide vaccine targeting isocitrate dehydrogenase 1 mutation in recurrent resectable low grade glioma patients.  Abstract ATIM-31.  Neuro-Oncology 21(Suppl 6):vi8, 2019.
  3. Peters, K., Lipp, E., Broadwater, G., Herndon J. II, Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Affronti, M.:  Clinical characteristics of low grade glioma patients with non-canonical IDH1 and IDH2 mutations.  Abstract NCOG-38. 2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii137, 2020.
  4. Weant, E., Woodring, S., Randazzo, D.M., Friedman, H.F., Desjardins, A., Vlahovic, G., Healy, P.,  Herndon, J.E. II , McSherry, F., Lipp, E.,Miller, E., Cone, C., Kim, J.Y., Southerland, C., Brown, C., Carter, M., Johnson, M.P., Peters, K.B, and Affronti, M.L.,:  Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.  Abstract MASCC-EP178.  2017 MASCC Annual Meeting, June 22-24, 2017, Washington DC. Supp. Care Cancer 25, Suppl. 2: S266, 2017.
  5. Desjardins, A., Randazzo, D., Peters, K.B., Johnson, M.O., Massey, W., Herndon, J.E. II, McSherry, F., Lipp, E.S., Nadler, P., Horak, I.D., Friedman, H.S.: Phase 2 Study of SYM004 for Adult Patients with Recurrent Glioblastoma (GBM). Abstract ACTR-64. 2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi303, 2017.
  6. Johnson, M.O., Kirkpatrick, J.P., Weant, M.P., Dunn-Pirio, A., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.:  A retrospective, single institution study of central neurocytoma (2004-2016): survival, treatment, and supportive care. Abstract RARE-25.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi215, 2017.
  7. Weant, M.P., Kirkpatrick, J., Johnson, M., Dunn-Pirio, A., Healy, P., Herndon, J.E. II, Lipp, E.S., Fountain, E., Desjardins, A., Randazzo, D., Friedman, H.S., Peters, K.B.:  Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma. Abstract RARE-36.  2017 SNO Annual Meeting, November 16-19, 2017, San Francisco, CA.  Neuro-Oncology 19(Suppl 6):vi217, 2017.
  8. Vaslow, Z., Peters, K., Kirkpatrick, J., McSherry, F., Herndon, J. II, Lipp, E., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., and Friedman, H.S.: Long-term outcomes of adult patients with ependymoma.  Abstract 150.  2018 70th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.
  9. Inamullah, O., Kirkpatrick, J., Healy, P., Lipp, E., Johnson, M., Ashley, D., Randazzo, D., Friedman, H. and Peters, K.:  Adult pilocytic astrocytoma: clinical management and prognostic factors.  Abstract 158.  2018 70th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.
  10. Peters, K.B., Kirkpatrick, J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., Panta, S., Lipp, E., Healy, P., Herndon, J., Spasojevic, I., Penchev, S., Gad, S., Silberstein, D., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D. and Crapo, J.:  Phase I dose escalation trial of the safety of BMX-001 concurrent with radiation therapy and temozolomide in newly diagnosed patients with high-grade glioma.  Abstract ACTR-28.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi17, 2018.
  11. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Thomas, L., Threatt, S., Bullock, C., Herndon, J., Boulton, S., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.:  Dose escalation trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).  Abstract ATIM-36.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi9, 2018.
  12. Johnson, M., Kirkpatrick, J., Weant, M., Vaslow, Z., Lipp, E., Herndon, J., McSherry, F., Desjardins, A., Randazzo, D., Friedman, H., Ashley, D., and Peters, K.:  Treatment patterns, outcomes and prognostic indicators in elderly patients with glioblastoma: a retrospective single institution analysis.  Abstract HOUT-19.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi117, 2018.
  13. Randazzo, D., Kirkpatrick, J., McSherry, F., Herndon, J., Affronti, M., Johnson, M., Vaslow, Z., Lipp, E., Desjardins, A., Friedman, H., and Peters, K.:  Psychosocial distress in patients with recurrent meningiomas.  Abstract QOLP-13.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi217, 2018.
  14. Vaslow, Z., Kirkpatrick, J., Affronti, M., Healy, P., Herndon, J., Lipp, E., Thomas, L., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Peters, K.:  Clinical and histopathological characteristics of young adults with glioblastoma at diagnosis.  Abstract RARE-16.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi239, 2018.
  15. Kang, J., Swisher, C., Kirkpatrick, J., Herndon, J. II, Lipp, E., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., and Peters, K.:  Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study.  2019 AAN Annual Meeting, May 4-10, 2019, Philadelphia, PA. 
  16. Desjardins, A., Gromeier, M., Herndon, J.E. II, Randazzo, D., Threatt, S., Lipp, E.S., Miller, E.S., Jackman, J., Bolognesi, D.P., Friedman, A.H., Friedman, H.S., McSherry, F., Peters, K.B., Johnson, M.O., Sampson, J.H., Ashley, D.M., and Bigner, D.D.:  Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): experience with retreatment of survivors from the phase I trial.  Abstract 2060.  2019 ASCO Annual Meeting, May 31 – June 4, 2019, Chicago, IL.  J Clin Oncol 37(15s):101s, 2019.
  17. Lee, J.W., Johnson, M.O., Kirkpatrick, J.P., McSherry, F., Herndon, J., Lipp, E., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D., Peters, K.B.:  Outcomes following adjuvant radiation therapy in elderly patients with glioblastoma: a retrospective single institution analysis.  2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, McCormick Place West, Chicago, IL, September 15 – 18, 2019.
  18. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Threatt, S., Bullock, C., Jackman, J., Healy, P., Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.:  Dose finding and dose expansion trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).  Abstract ATIM-24.  Neuro-Oncology 21(Suppl 6):vi6, 2019.
  19. Barbour, A., Healy, P., Lipp, E., Herndon, J., Thomas, L., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., Friedman, H., Kirkpatrick, J., and Peters, K.:  Characteristics of short-term survival in patients with glioblastoma: a retrospective analysis.  Abstract HOUT-21.  Neuro-Oncology 21(Suppl 6):vi116, 2019.
  20. Johnson, M., Ramirez, L., Herndon, J., Massey, W., Lipp, E., Affronti, M., Kim, J.-Y., Friedman, H., Desjardins, A., Randazzo, D., Ashley, D., Casarette, D., and Peters, K.:  A time-based model of early palliative care intervention in patients with newly diagnosed glioblastoma, a single institution feasibility study.  Abstract QOLP-18.  Neuro-Oncology 21(Suppl 6):vi201, 2019.
  21. Randazzo, D., Jackman, J., Herndon, J., Affronti, M., Lipp, E., Cort, N., Desjardins, A., Johnson, A., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.:  Mindfulness meditation practice in malignant glioma patients throughout concomitant radiation and temozolomide: a feasibility study.  Abstract QOLP-29.  Neuro-Oncology 21(Suppl 6):vi204, 2019.
  22. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K.B., Johnson, M.O., Threatt, S., Bullock, C.A., Herndon, J.E. II, Healy, P., Lipp, E.S., Sampson, J.H., Friedman, A.H., Friedman, H.S., Ashley, D.M., and Bigner, D.D.: Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Abstract 2566.  2020 ASCO Virtual Annual Meeting, May 29 – 31, 2020.  J Clin Oncol 38(suppl), 2020.
  23. Thompson, E., Landi, D., Lipp, E., Balajonda, B., Herndon, J. II, Buckley, E., Flahiff, C., Jaggers, D., Schroeder, K., Randazzo, D., Desjardins, A., Johnson, M., Peters, K., Khasraw, M., Malinzak, M., Mitchell, D., Ashley, D., and Sampson, J.:  Peptide vaccine directed to CMV PP65 for treatment of recurrent malignant glioma and medulloblastoma in children and young adults:  preliminary results of a phase I trial.  Abstract CTIM-21.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii37, 2020.
  24. Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Landi, D., Khasraw, M., Threatt, S., Bullock, C., Herndon, J. II, Lipp, E., Sampson, J., Friedman, A., Friedman, H., Ashley, D., and Bigner, D.:  A phase I trial of D2C7-IT in combination with atezolizumab in recurrent WHO grade IV malignant glioma (MG).  Abstract CTIM-23.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii38, 2020.
  25. Johnson, M., Herndon, J. II, Lipp, E., Affronti, M., Desjardins, A., Bhattacharya, M., Friedman, H., Ashley, D., Peters, K., and Randazzo, D.:  Patterns of distress in older patients with glioblastoma:  a follow-up to a single institution cross-sectional study of distress in primary brain tumor patients.  Abstract NCOG-23.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii134, 2020.
  26. Patel, M., Peters, K., Lipp, E., Low, J., Herndon, J. II, Broadwater, G., Johnson, M., Randazzo, D., Kim, J-Y., and Affronti, M.:  Olanzapine for refractory chemotherapy-induced nausea and vomiting in malignant glioma patients.  Abstract QOLP-05.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii175, 2020.
  27. Randazzo, D., Buckley, E., Herndon, J. II, Cort, N., Affronti, M., Lipp, E., Desjardins, A., Johnson, M., Landi, D., Ashley, D., Friedman, H., Glass, O., Porter, L., and Peters, K.:  A feasibility study utilizing mindfulness meditation during concomitant chemoradiation in malignant glioma patients: health-related quality of life (HRQOL) results.  Abstract QOLP-20.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii179, 2020.
  28. Peters, K., Randazzo, D., Johnson, M., Kim, J-Y., Patel, M., and Affronti, M.:  Engaging patients and caregivers to improve the importance and quality of supportive care research in neuro-oncology.  Abstract QOLP-24.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii180, 2020.

1. Johnson, M.O., Kirkpatrick, J.P., Patel, M.P., Desjardins, A., Randazzo, D., Friedman, H.S., Ashley, D.M., and Peters, K.B.:  The role of chemotherapy in the treatment of central neurocytoma.  CNS Oncol. Published online ahead of print November 5, 2019.

2. Patel MP, Kirkpatrick JP, Johnson MO, Healy P, Herndon JE 2nd, Lipp ES, Miller ES, Desjardins A, Randazzo D, Friedman HS, Ashley DM, Peters KB. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. J Neurooncol. 2020 Apr;147(2):477-483. doi: 10.1007/s11060-020-03446-3. Epub 2020 Mar 5. PMID: 32140975.

3. Lee JW, Kirkpatrick JP, McSherry F, Herndon JE II, Lipp ES, Desjardins A, Randazzo DM, Friedman HS, Ashley DM, Peters KB, Johnson MO: Adjuvant radiation in older patients with glioblastoma: a retrospective single institution analysis. Front. Oncol. 2021 Feb 25:11:631618. doi: 10.3389/fonc.2021.631618. eCollection 2021.  PMID: 33732649.

 

10/2016-9/2017

1 year as fellow

Assistant Professor

Duke University Medical Center

Durham, NC

Zachary Vaslow, MD

Adult Neurology

1. Vaslow, Z., Peters, K., Kirkpatrick, J., McSherry, F., Herndon, J. II, Lipp, E., Johnson, M., Ashley, D., Desjardins, A., Randazzo, D., and Friedman, H.S.: Long-term outcomes of adult patients with ependymoma.  Abstract 150.  2018 70th AAN Annual Meeting, April 21-27, 2018, Los Angeles, CA.

2. Johnson, M., Kirkpatrick, J., Weant, M., Vaslow, Z., Lipp, E., Herndon, J., McSherry, F., Desjardins, A., Randazzo, D., Friedman, H., Ashley, D., and Peters, K.:  Treatment patterns, outcomes and prognostic indicators in elderly patients with glioblastoma: a retrospective single institution analysis.  Abstract HOUT-19.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi117, 2018.

3. Randazzo, D., Kirkpatrick, J., McSherry, F., Herndon, J., Affronti, M., Johnson, M., Vaslow, Z., Lipp, E., Desjardins, A., Friedman, H., and Peters, K.:  Psychosocial distress in patients with recurrent meningiomas.  Abstract QOLP-13.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi217, 2018.

4. Vaslow, Z., Kirkpatrick, J., Affronti, M., Healy, P., Herndon, J., Lipp, E., Thomas, L., Johnson, M., Randazzo, D., Desjardins, A., Friedman, H., Ashley, D., and Peters, K.:  Clinical and histopathological characteristics of young adults with glioblastoma at diagnosis.  Abstract RARE-16.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi239, 2018.

1. Vaslow, Z., and Peters, K.B.:  Low-grade gliomas.  MedLink Neurol., accepted for publication July 2020.

 

07/2017-06/2018

1 year

Medical Director of Neuro-Oncology, Cone Health

Greensboro, NC

Justin Low, MD PhD

Adult Neurology

  1. Low, J., Kirkpatrick, J., and Peters, K.: Pineal parenchymal tumors of intermediate differentiation treated with ventricular radiation and temozolomide.  2019 AAN Annual Meeting, May 4-10, 2019, Philadelphia, PA
  2. Patel, M., Peters, K., Lipp, E., Low, J., Herndon, J. II, Broadwater, G., Johnson, M., Randazzo, D., Kim, J-Y., and Affronti, M.:  Olanzapine for refractory chemotherapy-induced nausea and vomiting in malignant glioma patients.  Abstract QOLP-05.  2020 SNO Virtual Meeting, November 19-21, 2020.  Neuro-Oncology 22(Suppl 2):ii175, 2020.

1. Low, J.T., and Peters, K.B.:  Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.  CNS Oncol.  Published online ahead of print March 6, 2020.

2. Low JT, Wang S-H, Peters KB: Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.  CNS Oncol. Published online ahead of print April 2021.

3. Low JT, Kirkpatrick JP, Peters KB. Pineal Parenchymal Tumors of Intermediate Differentiation Treated With Ventricular Radiation and Temozolomide. Adv Radiat Oncol. 2021 Sep 29;7(1):100814. doi: 10.1016/j.adro.2021.100814. PMID: 34746517; PMCID: PMC8554459.

 

07/2018-06/2020

Assistant Professor

Duke University Medical Center

Durham, NC

Kristen Batich, MD PhD

Medical Oncology

1.Batich, K.A., Riedel, RF., Kirkpatrick, J.P., Tong, B.C., Eward, W.C., Tan, C.L., Pittman, P.D., McLendon, R.E., and Peters, K.B.:  Recurrent extradural myxopapillary ependymoma with oligometastatic spread.  Front. Oncol.  Published online ahead of print November 28, 2019.

2.Vlahovic, G., Archer, G., Lally-Goss, D., Reap, E., Batich, K., Desjardins, A., Peters, K., Ranjan, T., Healy, P., Herndon, J. II, Friedman, A., Friedman, H., Bigner, D., and Sampson, J.:  Pilot study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).  Abstract IT-34.  2014 SNO Annual Meeting, November 13-16, 2014, Miami, FL.  Neuro-Oncol. 16, Suppl. 5: v117, 2014.

3.Batich, K., Ashley, D., Archer, G., Sanchez-Perez, L., Norberg, P., Congdon, K., Herndon, J., McSherry, F., Gemberling, S., Hesler, R., Jaggers, D., Van, R., Parker, J., Peters, K., Desjardins, A., Friedman, H., and Sampson, J.:  Enhancing vaccine responses with dose-intensified temozolomide in glioblastoma:  initiation of the I-ATTAC trial.  Abstract RBTT-02.  2018 SNO Annual Meeting, November 15-18, 2018, New Orleans, LA.  Neuro-Oncology 20(Suppl 6):vi234, 2018.

4.Batich, K., Wang, S-H.J., Salacz, M., and Peters, K.: Synchronous diagnosis of multicentric glioma with distinct molecular profiles.  2021 AAN Virtual Annual Meeting, April 17-22, 2021.

5.Batich, K., Mitchell, D., Healy, P., Herndon, J., Broadwater, G., Michael, G., Huang, M-N., Hotchkiss, K., Sanchez-Perez, L., Nair, S., Congdon, K., Norberg, P., Weinhold, K., Archer, G., Reap, E., Xie, W., Shipes, S., Albrecht, E., Peters, K., Randazzo, D., Johnson, M., Landi, D., Desjardins, A., Friedman, H., Vlahovic, G., Reardon, D., Vredenburgh, J., Bigner, D., Khasraw, M., McLendon, R., Thompson, E., Cook, S., Fecci, P., Codd, P., Floyd, S., Reitman, Z., Kirkpatrick, J., Friedman, A., Ashley, D.M., and Sampson, J.:  Reproducibility of clinical trials using CMV-targeted dendritic cell vaccines in patients with glioblastoma. Abstract CTIM-10.  2021 SNO Annual Meeting, November 18-21, 2021.  Neuro-Oncology 23(Suppl 6):vi51, 2021.

 

1.Batich KA, Riedel RF, Kirkpatrick JP, Tong BC, Eward WC, Tan CL, Pittman PD, McLendon RE, Peters KB. Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. Front Oncol. 2019 Nov 28;9:1322. doi: 10.3389/fonc.2019.01322. PMID: 31850213; PMCID: PMC6892774.

 

2. Vaios EJ, Batich KA, Buckley AF, Dunn-Pirio A, Patel MP, Kirkpatrick JP, Goudar R, Peters KB. Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma. Oncotarget. 2022 Mar 29;13:576-582. doi: 10.18632/oncotarget.28222. PMID: 35359747; PMCID: PMC8963718.

 

07/2020-Present

Emily Hanzlik, MD

Pediatric Neurology
1. Hanzlik E, Archambault B, Dairi M, Schroeder K, Patel M, Lipp ES, Boucree S, Peters K, Ashley D, Landi D. LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS. Neuro Oncol. 2021 Jun 1;23(Suppl 1):i32–3. doi: 10.1093/neuonc/noab090.132. PMCID: PMC8168132.

07/2020-06/2022

St. Jude’s Hospital Memphis, TN-Faculty

Madison Shoaf, MD

Adult Neurology

1. Shoaf, M., and Peters, K.:  High grade glioma of the spinal cord: a cases series of rare malignancy.  2021 AAN Virtual Annual Meeting, April 17-22, 2021. 

1.Shoaf M and Peters, KB. Clinical trial of oncolytic viruses in glioblastoma. Advances in Oncology. 2022 May. 2, 1: 139-158. doi.org/10.1016/j.yao.2022.02.004

07/2020-06/2022

Emory University, Atlanta, GA-Faculty

Katherine Ryan, DO

Pediatric Hematology/ Oncology

07/2021-Present

Avani Mangoli, DO

Pediatric Hematology/ Oncology

07/2022-Present

Kaleigh Fetcko-Fayad, MD

Adult Neurology

07/2022-Present